<?xml version="1.0" encoding="UTF-8"?>
<p>The 78-week (18-month) duration per patient provides sufficient duration to evaluate efficacy and safety and is consistent with industry and National Institute of Health supported phase II trials in AD. Total study duration is 5 years.</p>
